Terms ending in 2027
Every in-force patent on Eyepoint, Inc.'s record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,926,367 | ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF In force · High confidence | Eyepoint, Inc. | In force | High confidence | |
| US 11,814,425 | ANTIBODIES THAT BIND HUMAN PROTEIN TYROSINE PHOSPHATASE beta (HPTPbeta) AND USES THEREOF In force · Medium confidence | Eyepoint, Inc. | In force | Medium confidence | |
| US 8,524,235 | Method for Treating Coronary Artery Disease Using Antibody Binding Human Protein Tyrosine Phosphatase Beta(HPTPbeta) In force · High confidence | Eyepoint, Inc. | In force | High confidence | |
| US 7,589,212 | Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use In force · Medium confidence | Eyepoint Pharmaceuticals, Inc. | In force | Medium confidence | |
| US 7,622,593 | Human Protein Tyrosine Phosphatase Inhibitors an Methods of Use In force · Medium confidence | Eyepoint Pharmaceuticals, Inc. | In force | Medium confidence | |
| US RE46,592 | Human Protein Tyrosine Phosphatase Inhibitors and Methods of Use In force · Low confidence | Eyepoint Pharmaceuticals, Inc. | In force | Low confidence | |
| US 8,871,241 | Injectable sustained release delivery devices In force · High confidence | Eyepoint, Inc. | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.